Access to a vital therapy, known for treating adults with multiple myeloma, an incurable form of blood cancer, is being stalled in Canada, health advocates say.

The one-time treatment, called CAR T-cell or Carvykti, has been successful in the United States, helping individuals live longer; however, in September 2025, national reimbursement discussions between the drug manufacturer, Johnson & Johnson, and the Pan-Canadian Pharmaceutical Alliance ended without an deal.

The failed agreement meant thousands of Canadians battling multiple myeloma who would qualify for the treatment would be left to pay for the drug out of pocket, with the therapy costing $632,455, according to Johnson & Johnson.

“At some point, they just couldn’t agree on the price that they were willing to pay or offer the

See Full Page